Skip to main content

Don’t forget your homework!

10th September 2021

Submitted by:

Andrew Warmington

In speciality chemicals, doing your MA&D ‘homework’ means much more than it used to, says Lauren McCallum, solution manager for SAP’s Chemical Industry business unit

On 23 August, Lanxess announced its acquisition of IFF’s microbial control business. This was just days after the German speciality chemical company completed its acquisition of Emerald Kamala, the world’s largest benzoic acid producer. Lanxess had already bought disinfectant producers Theseo and Intace in early 2021. Those purchases were just a few of several other mergers, acquisitions, and divestitures (MA&D) the company has undertaken since its own formation as a Bayer divestiture in 2004, the biggest being its  acquisition of Chemtura in 2017.

None of this was too surprising to those of us in the speciality chemical world. In a March call, Lanxess CEO Matthias Zachert told analysts, “Our focus is on so-called bolt-on, midsize acquisitions… However, given a good, attractive M&A opportunity, we wouldn’t shy away from it.”

Given the volume of MA&D activity in speciality chemicals, I could have chosen any number of examples here. But in that same conference call, Zachert added, “We have done our homework and can act from a position of strength in regards to M&A.”

That strength, as Lanxess has made clear, was substantially built on the digital transformation that was part of that homework. Doing one’s homework means much more than it used to. In the case of Lanxess and many other companies I have watched merge, acquire, and divest in recent years, it is no longer just about traditional due diligence. T

he speciality chemical industry – and the chemicals industry in general – has become one in which preparing for, executing, and then monitoring the fruits of MA&D has become something of a core business function. If that sounds overblown, consider that Deloitte counted 501 mergers and acquisitions in the global chemical industry in 2020 – down about 14% from the prior year due to the COVID-19 pandemic.

Speciality chemicals comprised a full quarter of that activity, with fertilisers and agricultural chemicals making up another 10% of it. Megadeals were scarce – all but eight were less than $1 billion in value. Mid-market deals of the sort Lanxess typically purses predominated. When the numbers come in, 2021 will surely have seen a rebound: all but one of the 35 chemical-industry executives Deloitte interviewed in late 2020 said they were likely to be pursuing M&A deals in 2021.

The reasons the speciality chemical industry so busily acquires, merges, and divests are familiar enough. The industry is characterised by long R&D cycles and intense regulatory oversight. To enter new geographic markets and expand product portfolios into new market segments, buying in is often more appealing than the costly grind of developing or expanding in-house.

As the competitive landscape changes, chemical companies want to shift and sharpen their strategic focus and reassess strengths and weakness vis-à-vis market opportunities. These opportunities are frequently driven by the need to adapt to consumer tastes, for example, through new emphases on sustainable products and production.

The flavour and fragrance industry segment is a particularly good example here, as consumer desire for ‘natural’ and healthy ingredients has driven a flurry of acquisitions over the past years, from IFF’s acquisition of Frutarom and their purchase last year of DuPont’s Nutrition & Bioscience business unit to both Givaudan and Firmenich purchasing stakes in Robertet, a French natural ingredients company.

Environmental, social, and governance issues – not least related to carbon emissions – are starting to creep or stomp into the conversation, too. You can talk to ExxonMobil Chemicals about that. And, of course, we want to (and must) achieve ‘synergies’, perhaps the most popular inhabitant of the MA&D press release.

In Lanxess’s case, a big part of its homework was done well before these recent acquisitions. When it bought Chemtura – this was a $2.6 billion megadeal – Lanxess faced the prospect of integrating its new addition with both companies on their own customised versions of the same ageing ERP system. It saw this as a good time to start afresh. The new system ushered in simplified, harmonised, standardised processes that Lanxess and its new acquisition would share.

As Lanxess recognised, systems designed to support the speciality chemical company of a decade or longer ago no longer do such a great job supporting today’s business, which demands extreme speed and agility across product and service portfolios. In addition to the day-to-day business benefits of this streamlining and modernising, business process standardisation played right into its MA&D business function. ‘Plug-and-play’ will always be a pipe dream with something as complex as a chemical-industry merger, but Lanxess’s IT investment is paying dividends here.

When you standardise on industry-standard processes, integrating new businesses becomes much, much easier. Moreover, these systems also vastly expand upon legacy systems’ MA&D support functions. While legacy ERP systems did provide a helping hand in integrating new acquisitions and, afterward, providing insights into the successes and not-quite-successes of that integration, they can do much more now.

The new systems support scenario simulation related to potential opportunities on both the M&A and divestiture side. Real-time financial analytics and simulations based on diverse, timely data help executives see what selling a business unit – or adding one – might ultimately do for their company. These systems provide a window into the profitability of a company’s existing product portfolio right down to individual products that, in this business, can number in the thousands and involve the ‘same’ product being made in distant plants at varying costs with different margins in diverse markets.

The writer Shel Silverstein was not talking about the speciality chemical business, but in ‘The Missing Piece’ he certainly recognised that the secret of a successful partnership is first knowing your own strengths and weaknesses. In this business, chemical companies have to know themselves down to the product and the penny.

The importance of state-of-the-art systems in successful MA&D also has to do with their inherent capabilities and the flexibility their data models provide. Put simply, these systems combine rock-solid core chemical-business processes amid a constellation of shared services (think HR, procurement, and logistics) that operate as cloud applications around that core. I have seen this separation enable far easier post-acquisition integration.

Finally, once a merger or acquisition is wrapped up, these systems’ monitoring capabilities can confirm whether the business processes so painstakingly crafted for the combined entity are being used, and if so, whether those processes are helping save money and make money. Lanxess has done its homework, but it is not the only speciality-chemical firm that can boast as much: Albemarle, Axalta, DuPont, FMC, IFF, and Versum (now part of Merck KGaA) are a few other examples among many.

On the IT front, that homework involves many months of process redesign, integration, testing, and conversion work, as well as change management across vast swaths of an organisation. As Lanxess and others have shown, these systems have helped them pursue M&A strategies with unprecedented confidence, and they’re taking full advantage of it. It is a safe bet that they will not be the last to do so.

Contact:

Lauren McCallum

SAP

[email protected]

www.sap.com

Feature article – Saltigo rides out the cycle

Market and sustainability trends are positive drivers for Saltigo, despite the agro downturn. Andrew Warmington met up with the new CEO at Chemspec Europe

Submitted by:

Andrew Warmington

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical active ingredient (AI) manufacturing to its wholly owned subsidiary UPL Spec

Submitted by:

Andrew Warmington

Nippon Shokubai opens Indonesian plant

Japan’s Nippon Shokubai has officially opened a 100,000 tonnes/year acrylic acid (AA) plant that was built at a cost of about $200 million at Cilegon, Banten, Indonesia.

Submitted by:

Andrew Warmington

CABB to invest at Finnish agro site

The CABB Group has said that it will invest over €50 million by 2025 to expand facilities at its agrochemical manufacturing site in Kokkola, Finland.

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production planning of superabsorbent polymers (SAPs) based on acrylic acid, and has started operati

Submitted by:

Andrew Warmington

adcs

Three invest further into ADCs

Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.

Submitted by:

Andrew Warmington

Cambrex exits drug product

CDMO Cambrex has sold its Drug Product business unit to Noramco. Terms were not disclosed.

Submitted by:

Andrew Warmington

Siegfried breaks ground on R&D centre

Siegfried has broke ground for its new global R&D centre for drug substances at its site in Evionnaz, Switzerland.

Submitted by:

Andrew Warmington

Drug product centre opens

Following two years of construction work, CDMO Siegfried has officially opened its new development centre for drug products at its sites in Barberà del Vallès and El Masnou near Barcelona.

Submitted by:

Andrew Warmington

Evonik realigns Health Care

In order to “maximise customer centricity and market focus” and continue an ongoing transition into “a system solutions partner for the pharmaceutical and biotech industries”, Evonik has divided it

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants under the trade names AmphiCare and AmphiClean.

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based subsidiary of Seqens.

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in Austria have co-developed a computer-assisted regression model to improve enzyme performance and

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU and the Bio-based Industries Consortium (BIC) that funds projects advancing competitive circular bi

Submitted by:

Andrew Warmington

Investment in Tanasote plant

Octowood, a part of the Sweden’s Rundvirke Industrier Group, has invested in a new treatment plant using Arxada’s wood preservative, Tanasote.

Submitted by:

Andrew Warmington

Rhamnolipid milestone reached

Evonik has manufactured the first product from its industrial-scale biosurfactants facility at Slovenská Lupca in Slovakia.

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach Group in a move that it said would “create a global pigment company, combining SCIL’s ope

Submitted by:

Andrew Warmington

Lanxess to continue pigment production

Lanxess has reversed a decision to sell the chromium oxide pigments business at the Krefeld-Uerdingen site in Germany, preserving 50 jobs there.

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw materials, has announced a strategic collaboration with Japan’s Takasago, a large player in th

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site in Guangzhou. This triples its manufacturing capacity for fragrances and establis

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable fragrance ingredients from renewable carbon, with US-based LanzaTech, which describes i

Submitted by:

Andrew Warmington

Kao boosts jasmine fragrance

Japan's Kao Corporation is to double capacity for the synthetic fragrance methyl dihydrojasmonate (MDJ) at its site in Olesa, Spain, by adding a second production facility.

Submitted by:

Andrew Warmington

Merck KGaA “in a strong strategic position”

At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitio

Submitted by:

Andrew Warmington

Suez joins Global Impact Coalition

Suez, which describes itself as “a global leader in circular solutions for water and waste”, has joined the Global Impact Coalition (GIC).

Submitted by:

Andrew Warmington

Chemours opens battery lab

Chemours has opened Chemours Battery Innovation Centre (CBIC) at the Chemours Discovery Hub in Newark, Delaware.

Submitted by:

Andrew Warmington